Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
ConclusionIC eptifibatide might improve the reperfusion markers during PPCI for STEMI patients presenting after 3 h from onset of symptoms. A large randomized study is recommended to ascertain the benefits of IC eptifibatide in late presenters on clinical outcomes.
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Angioplasty | Cardiology | Coronary Angioplasty | Eptifibatide | Heart | Heart Attack | Integrilin | Percutaneous Coronary Intervention | Study